Physician profile
Nhan Luu
NPI 1598060337
$8,874.23
in general payments reported to CMS, 2019-2025
24 companies · $2,204 in 2025
The $2,204 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $95.55 · 2021: $547 · 2022: $1,082 · 2023: $2,234 · 2024: $2,096 · 2025: $2,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,995 · Education: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,995.33 |
| Education | $538.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,085.82 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $885.28 | 2019-2025 | Farxiga, Lokelma, Brilinta |
| Ani Pharmaceuticals, INC. | $871.44 | 2023-2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $847.82 | 2019-2025 | Auryxia, Vafseo |
| Novartis Pharmaceuticals Corporation | $818.27 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $588.93 | 2023-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $559.29 | 2022-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $526.30 | 2022-2025 | Tarpeyo |
| Amgen INC. | $514.51 | 2021-2025 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $385.09 | 2019-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $352.62 | 2019-2023 | Velphoro |
| Alexion Pharmaceuticals, INC. | $307.93 | 2019-2024 | Ultomiris |
| Aurinia Pharma U.S., INC. | $268.22 | 2021-2025 | Lupkynis |
| Ardelyx, INC. | $203.21 | 2023-2025 | Ibsrela |
| Horizon Therapeutics Plc | $138.24 | 2021-2023 | Krystexxa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $137.43 | 2019-2024 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $99.08 | 2023-2025 | Filspari |
| Genzyme Corporation | $95.64 | 2023-2024 | |
| Nxstage Medical, INC. | $77.89 | 2021-2025 | Nxstage System One, Liberty Select Cycler, Pureflow Sl |
| Amag Pharmaceuticals, INC. | $36.26 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $27.25 | 2023 | Acthar |
| Sk Life Science, INC. | $21.60 | 2023 | |
| Collegium Pharmaceutical, INC. | $15.28 | 2022 | |
| Pfizer INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nhan Luu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.